Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting
“The data presented at AACR provide important new models and mechanistic insights that inform our planned development efforts to evaluate the ability of microbiome therapy to augment immune checkpoint inhibitors,” said David Cook, Ph.D., Chief Scientific Officer and Executive Vice President of Research at Seres. “The insights described in this presentation will guide the continued development of SER-401, which we expect to enter clinical development later this year. Our objective is to use our microbiome therapeutic approach to improve the efficacy of immunotherapy in patients with life-threatening cancers.”
Seres presented results from preclinical studies designed to evaluate the impact of various consortia of bacterial species on the anti-tumor immune response in murine models following treatment with an anti-PD-1 checkpoint inhibitor. Results demonstrated that both germ-free mice lacking a microbiome and antibiotics-treated mice with a dysbiotic microbiome, failed to mount an effective anti-tumor response following treatment with an anti-PD-1 checkpoint inhibitor. The response to anti-PD-1 was restored in germ-free as well as antibiotics-treated mice by introducing a diverse microbiome, and was driven by increased entry of tumor-infiltrating lymphocytes into the tumor; specifically, CD8+ T effector cells. Current pre-clinical efforts are focused on optimizing specific microbiome compositions based on functional and phylogenetic information to inform the development of therapeutic candidates.
Seres is developing SER-401, a preclinical stage oral microbiome therapy
comprising a consortium of live bacteria to improve the efficacy and
safety of immunotherapy. Through a collaboration with
About Seres Therapeutics
References
1. Sceneay,
View source version on businesswire.com: https://www.businesswire.com/news/home/20180417005622/en/
Source:
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Vice
President, Investor Relations and Corporate Communications
ctanzi@serestherapeutics.com